Peptide-Based Immune Checkpoint Inhibitors

Peptide Checkpoint Inhibitors

$200B+ projected checkpoint inhibitor market by 2030

Monoclonal antibody checkpoint inhibitors have transformed cancer treatment, but their size, cost, and limited tumor penetration have driven development of peptide alternatives that could expand access and improve solid tumor responses.

Lei et al., Pharmaceutics, 2025

Lei et al., Pharmaceutics, 2025

View as image

Immune checkpoint inhibitors have become the backbone of modern cancer immunotherapy. Antibodies targeting PD-1 (nivolumab, pembrolizumab), PD-L1 (atezolizumab, durvalumab), and CTLA-4 (ipilimumab) have produced durable responses in cancers from melanoma to lung to bladder. But these antibodies are large proteins, roughly 150 kilodaltons, and their size creates practical limitations: poor penetration into solid tumors, manufacturing costs that push annual treatment above $150,000 per patient, cold-chain storage requirements, and immune-related adverse events driven by prolonged systemic exposure. Peptide-based checkpoint inhibitors, typically 1 to 5 kilodaltons, aim to deliver the same checkpoint blockade with better tumor penetration, lower production costs, and tunable pharmacokinetics. This article maps the full landscape of peptide approaches to checkpoint inhibition, from linear peptides through macrocyclic inhibitors to combination strategies. For the specific PD-1/PD-L1 peptide inhibitor research, see Peptide PD-1/PD-L1 Inhibitors: Can Small Peptides Replace Large Antibodies?. For how peptide-MHC complexes present cancer targets, see How Peptide-MHC Complexes Present Cancer Targets to T-Cells.

Why Size Matters in Checkpoint Inhibition

The fundamental argument for peptide checkpoint inhibitors is physics. Monoclonal antibodies are roughly 150 kilodaltons and approximately 10 nanometers in diameter. Solid tumors are dense, heterogeneous tissues with elevated interstitial pressure and disorganized vasculature that impedes large molecule penetration. Antibody distribution within tumors is often confined to perivascular regions, leaving interior tumor cells unexposed to checkpoint blockade.

Peptides, at 1 to 5 kilodaltons and 1 to 2 nanometers, diffuse through tumor tissue more rapidly and uniformly. Lei et al.'s 2025 review in Pharmaceutics documented the advantages: peptides offer remarkable selectivity for cell-surface drug targets, robust infiltration into solid tumors, straightforward synthesis at lower cost, and tunable pharmacokinetic profiles.^[1] The review also noted that peptide therapeutics occupy an intermediate position between antibodies and small molecules, combining the target specificity of biologics with some of the tissue penetration advantages of small molecules.

The trade-off is binding affinity and half-life. Antibodies achieve picomolar binding affinities and circulate for weeks due to FcRn recycling. Peptides typically bind at nanomolar affinities and are cleared within hours. This means peptide checkpoint inhibitors may require more frequent dosing but could also produce fewer immune-related adverse events, since their shorter exposure window reduces the duration of systemic checkpoint blockade.

The clinical relevance of this trade-off depends on tumor type. In well-vascularized tumors like melanoma and renal cell carcinoma, antibody checkpoint inhibitors achieve reasonable tissue distribution and have produced impressive response rates. In poorly vascularized, stroma-dense tumors like pancreatic ductal adenocarcinoma and glioblastoma, antibody penetration is severely limited and response rates to checkpoint antibodies remain low. These hard-to-penetrate tumors represent the clearest clinical opportunity for peptide alternatives. The question is whether improved penetration can compensate for lower binding affinity and shorter duration, and that question can only be answered through head-to-head clinical comparisons that have not yet been conducted.

Direct PD-1/PD-L1 Peptide Inhibitors

The PD-1/PD-L1 axis has attracted the most peptide drug development activity because it is the most commercially successful checkpoint target and the interaction surface is relatively well characterized structurally.

AUNP12: The First Peptide PD-1/PD-L1 Inhibitor

AUNP12, a 29-amino acid branched peptide developed by Aurigene and Pierre Fabre, was the first peptide specifically designed to block the PD-1/PD-L1 interaction. The peptide achieved subnanomolar potency, with an EC50 of 0.72 nM in HEK293 cells expressing human PD-L2 and 0.41 nM in rat PBMC proliferation assays. AUNP12 demonstrated dose-dependent immune activation in preclinical models, restoring T-cell proliferation and cytokine production suppressed by PD-L1 signaling.

Shaabani et al.'s 2018 review in Expert Opinion on Therapeutic Patents catalogued the rapid expansion of peptide and macrocyclic PD-1/PD-L1 antagonists between 2015 and 2018, documenting dozens of patent filings from pharmaceutical companies seeking non-antibody checkpoint inhibitors.^[2] The review identified three structural classes: linear peptides derived from the PD-1/PD-L1 binding interface, cyclic peptides with constrained conformations for improved binding, and macrocyclic peptides with drug-like properties approaching those of small molecules. The pace of patent activity indicated that major pharmaceutical companies viewed peptide checkpoint inhibitors not as academic curiosities but as commercially viable drug candidates. Multiple companies including Bristol-Myers Squibb, Aurigene, and several Chinese biotechnology firms filed composition-of-matter patents claiming distinct peptide scaffolds for PD-1/PD-L1 blockade.

BMS-986189: Macrocyclic Peptide in the Clinic

Bristol-Myers Squibb's BMS-986189 represents the most clinically advanced macrocyclic peptide checkpoint inhibitor. This compound achieved an IC50 of 1.03 nM against PD-L1 and progressed to Phase 1 clinical testing. In healthy volunteers, BMS-986189 demonstrated near-complete peripheral PD-L1 occupancy at low plasma concentrations, consistent with its low picomolar binding affinity to PD-L1.

The limitation was pharmacokinetic: BMS-986189's short half-life necessitated once-daily subcutaneous administration, compared to the every-2-to-4-week intravenous dosing of antibody checkpoint inhibitors. For patients, this dosing frequency difference is meaningful: daily injections impose a treatment burden that biweekly or monthly infusions do not. BMS subsequently developed second-generation macrocyclic peptides (including BMS-986238) with improved half-lives while maintaining potency, incorporating albumin-binding modifications and PEGylation strategies to extend circulation time.

The BMS program demonstrated that the core pharmacology of peptide checkpoint blockade works at the cellular level. The remaining engineering challenge is making it work at the whole-body level: getting enough peptide to the tumor for long enough to produce clinical responses comparable to antibodies. This is fundamentally a drug delivery and medicinal chemistry problem rather than a target biology problem, and multiple optimization strategies (half-life extension, tumor-activated prodrugs, sustained-release formulations) are being pursued in parallel. For detailed analysis of PD-1/PD-L1-specific peptide inhibitors, see Peptide PD-1/PD-L1 Inhibitors: Can Small Peptides Replace Large Antibodies?.

Macrocyclic Peptide Design: Engineering Checkpoint Blockade

Macrocyclic peptides have emerged as the most promising structural class for checkpoint inhibition because cyclization addresses the two main weaknesses of linear peptides: proteolytic instability and conformational flexibility that reduces binding affinity.

Guardiola et al.'s 2021 study in Chemical Science described a target-templated de novo design approach for macrocyclic PD-1 inhibitors.^[3] Their method used the known crystal structure of the PD-1/PD-L1 complex to design macrocyclic peptides containing mixed D- and L-amino acids. The D-amino acid incorporation served two purposes: it expanded the conformational space available for binding optimization beyond what natural L-peptide sequences can achieve, and it increased resistance to proteolytic degradation since most endogenous proteases recognize and cleave only L-amino acid substrates. The resulting macrocycles achieved drug-like inhibition of the PD-1/PD-L1 interaction.

Tsuihiji et al.'s 2022 study in Pharmaceuticals extended the macrocyclic approach to CTLA-4, describing a rational strategy for designing peptidomimetic small molecules based on cyclic peptide structures targeting protein-protein interactions.^[4] The study used cyclic peptide scaffolds as starting points for medicinal chemistry optimization, systematically replacing peptide bonds with non-natural backbone modifications to improve oral bioavailability while maintaining checkpoint blocking activity. This peptidomimetic approach represents a bridge between pure peptide and small molecule checkpoint inhibitors.

Peptide Cancer Vaccines: The Other Side of Checkpoint Therapy

While peptide checkpoint inhibitors aim to release the brakes on existing anti-tumor immunity, peptide cancer vaccines aim to generate new anti-tumor immune responses. These two approaches are increasingly used in combination, and the vaccine side of peptide immunotherapy has produced more clinical data than direct peptide checkpoint blockade.

Neoantigen Peptide Vaccines

Personalized neoantigen vaccines represent the most tumor-specific approach. Neoantigens are peptides derived from tumor-specific mutations that are absent from normal tissues, making them ideal targets for immune recognition without autoimmune risk. Chen et al.'s 2020 review in Theranostics mapped the clinical landscape of personalized neoantigen vaccination using synthetic long peptides (SLPs).^[5] SLPs of 20-35 amino acids are taken up by dendritic cells, processed internally, and presented on both MHC class I and class II molecules, stimulating both CD8+ cytotoxic T cells and CD4+ helper T cells.

Qiu et al.'s 2018 study in Biomaterials demonstrated that neoantigen peptide delivery can be optimized with polymer nanoparticles. Their poly(propylacrylic acid)-peptide nanoplexes enhanced the immunogenicity of neoantigen cancer vaccines by promoting endosomal escape and improving antigen cross-presentation by dendritic cells.^[6] The delivery platform matters because free peptides administered subcutaneously are rapidly degraded by tissue proteases and may be presented by non-professional antigen-presenting cells in a tolerogenic rather than immunogenic context. Nanoparticle encapsulation protects peptides from degradation and ensures they reach dendritic cells in lymph nodes, where cross-presentation on MHC class I molecules activates the CD8+ cytotoxic T cells needed for tumor killing.

Shared Antigen Vaccines

Not all cancer peptide vaccines require personalization. Shared tumor-associated antigens like hTERT (human telomerase reverse transcriptase), HER2/neu, and gp100 are overexpressed across many tumor types. Lilleby et al.'s 2017 Phase I/IIa trial in Cancer Immunology, Immunotherapy tested an hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.^[7] Immune responses to hTERT were detected in 68% of patients, with a favorable safety profile supporting further development. The trial provided proof of concept that peptide vaccines targeting universally expressed tumor antigens can generate measurable anti-tumor immunity.

Razazan et al.'s 2017 study demonstrated a conjugated nanoliposome carrying the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in a BALB/c mouse model.^[8] The nanoliposome formulation enhanced peptide immunogenicity and produced tumor-protective immunity, illustrating how delivery technology can amplify peptide vaccine effectiveness. GP2 is a 9-amino acid peptide derived from the HER2/neu transmembrane domain that binds HLA-A2 and stimulates HER2-specific CD8+ T cells. In clinical trials, the GP2 vaccine has shown preliminary evidence of preventing breast cancer recurrence in HER2-positive patients, with a Phase 2 trial reporting zero recurrences in the vaccine arm at 5-year follow-up compared to an 11.9% recurrence rate in the placebo arm.

Combination Strategies: Peptides Plus Checkpoint Antibodies

The most immediate clinical impact of peptide immunotherapy in checkpoint inhibition is not replacing antibodies but enhancing them. Several combination approaches have produced data.

Yazdani et al.'s 2020 study in Vaccine showed that dendritic cells pulsed with gp100 peptide-decorated liposomes enhanced the efficacy of anti-PD-L1 antibody treatment in melanoma models.^[9] The peptide vaccine component generated tumor-specific T cells, while the checkpoint antibody prevented their exhaustion. Neither approach alone was as effective as the combination.

Amorelli et al.'s 2025 case report in Frontiers in Immunology described a neoantigen-targeting peptide vaccine combined with checkpoint inhibitor therapy that induced tumor regression in a cancer patient.^[10] While a single case report cannot establish efficacy, it demonstrated the feasibility and safety of the combination approach in a clinical setting.

Castro et al.'s 2024 study in the Journal of Immunology identified an optimized adjuvant combination for peptide-based checkpoint therapy. Their TLR9 plus STING agonist combination induced potent neopeptide T-cell immunity and improved checkpoint inhibitor responses in preclinical models.^[11] The adjuvant combination enhanced dendritic cell maturation and antigen cross-presentation, amplifying the immune response generated by peptide vaccination.

Esfahani et al.'s 2023 study in the Journal of Nuclear Medicine demonstrated a different combination: peptide receptor radiotherapy (PRRT) combined with immune checkpoint inhibitors for neuroendocrine tumors.^[12] PRRT uses radiolabeled somatostatin analog peptides (typically lutetium-177-DOTATATE) that bind somatostatin receptors overexpressed on neuroendocrine tumor cells, delivering targeted beta radiation directly to the tumor. The radiation-induced tumor cell death releases neoantigens and damage-associated molecular patterns that prime anti-tumor immune responses, which checkpoint inhibitors then sustain by preventing T-cell exhaustion. The combination improved outcomes in neuroendocrine tumors beyond either therapy alone, with higher response rates and longer progression-free survival. This PRRT-checkpoint combination illustrates a broader principle: peptide-based therapies and antibody checkpoint inhibitors are more likely to complement each other than compete.

Stapled Peptides: Disrupting Intracellular Checkpoints

While most checkpoint inhibitor development targets extracellular PD-1/PD-L1 and CTLA-4 interactions, intracellular protein-protein interactions also regulate immune checkpoint pathways. Stapled peptides, with their enhanced cell permeability and protease resistance, can access these intracellular targets.

Iyer et al.'s 2016 review in Current Medicinal Chemistry catalogued stapled peptides and small molecules designed to inhibit protein-protein interactions in cancer, including interactions in apoptotic pathways that determine whether immune-activated tumor cells actually die.^[13] For how the landmark Walensky et al. 2004 study in Science established the stapled peptide field with in vivo apoptosis activation, see the broader context in Anticancer Peptides: How They Selectively Kill Tumor Cells.

The convergence of extracellular checkpoint blockade (peptide PD-1/PD-L1 inhibitors) with intracellular pathway modulation (stapled peptides targeting apoptotic regulators) could address a key resistance mechanism: tumors that evade checkpoint therapy not because they avoid immune recognition but because they resist immune-mediated killing. Approximately 30-50% of patients who initially respond to antibody checkpoint inhibitors eventually develop resistance, and defective apoptotic pathways are among the most common resistance mechanisms identified. Stapled peptides that restore apoptotic sensitivity could re-sensitize resistant tumors to checkpoint-mediated immune attack.

The stapled peptide approach also opens targets that are inaccessible to antibodies. Intracellular proteins like Bcl-2 family members, MDM2, and beta-catenin all contribute to immune evasion through mechanisms that operate inside the tumor cell. Antibodies cannot cross cell membranes. Small molecules can, but often lack the selectivity needed to disrupt specific protein-protein interactions. Stapled peptides combine cell penetration with protein-protein interaction specificity, filling a therapeutic niche that neither antibodies nor traditional small molecules can occupy.

Bispecific Peptides: Bridging Targets

An emerging approach combines checkpoint blockade with other functions in a single peptide molecule. Bispecific peptides can simultaneously target PD-L1 and a second molecule, such as VEGFR2 (to combine checkpoint blockade with anti-angiogenesis) or a tumor-specific antigen (to localize checkpoint blockade to the tumor microenvironment). These dual-targeting designs are enabled by the synthetic flexibility of peptides, which can be readily modified to incorporate multiple binding domains.

The rationale for bispecific designs reflects a growing understanding that checkpoint blockade alone is insufficient for many cancers. Tumors create immunosuppressive microenvironments through multiple mechanisms: checkpoint ligand expression, angiogenic signaling that excludes immune cells, myeloid-derived suppressor cell recruitment, and metabolic competition for nutrients that T cells need to function. A bispecific peptide that blocks PD-L1 while simultaneously inhibiting VEGFR2 addresses two of these mechanisms with a single molecule. The manufacturing advantage is that a single bispecific peptide is simpler and cheaper to produce than two separate antibodies, while the pharmacokinetic advantage is that both activities are delivered to the same tissue locations simultaneously.

The engineering challenge is maintaining adequate binding affinity for both targets within a single peptide of manageable size. Current bispecific peptide designs typically sacrifice some affinity for each individual target compared to monospecific agents. Whether the simultaneous dual targeting compensates for reduced per-target potency is being tested in preclinical models across multiple tumor types. For the broader landscape of bispecific peptide design in cancer, see Bispecific Peptides in Cancer: Bridging Immune Cells and Tumors.

What Antibodies Still Do Better

Peptide checkpoint inhibitors are not positioned to replace antibodies across all applications. Several areas remain where antibodies have clear advantages.

Binding affinity and duration: Antibodies achieve picomolar affinities and weeks-long circulation. Even optimized macrocyclic peptides typically achieve low nanomolar affinities with hours-long half-lives. For cancers where sustained checkpoint blockade is critical, antibodies remain superior.

Fc-mediated effector functions: Antibodies like ipilimumab (anti-CTLA-4) work partly through Fc receptor-mediated depletion of regulatory T cells in the tumor microenvironment. Peptides lack the Fc domain and cannot recruit these effector mechanisms.

Clinical track record: Over a dozen antibody checkpoint inhibitors have FDA approval across dozens of cancer indications. No peptide checkpoint inhibitor has been approved. The regulatory path for peptide alternatives is less established.

Combination with existing regimens: Current clinical protocols for antibody checkpoint inhibitors have been optimized over years of trials involving tens of thousands of patients. Oncologists have established dosing schedules, biomarker-guided patient selection (PD-L1 expression, microsatellite instability, tumor mutational burden), and combination regimens with chemotherapy and targeted therapy. Integrating peptide alternatives would require new dose-finding studies, biomarker revalidation, and sequencing optimization, essentially rebuilding the clinical evidence base from scratch for each indication.

Where Peptides Could Win

Peptide checkpoint inhibitors have theoretical advantages in specific clinical scenarios that antibodies serve poorly.

Solid tumor core penetration: Pancreatic, ovarian, and glioblastoma tumors have dense stroma that limits antibody penetration. Smaller peptides could achieve more uniform distribution throughout the tumor mass.

Cost and access: Antibody checkpoint inhibitors cost $100,000-$250,000 per year per patient. Peptide synthesis is substantially cheaper than antibody manufacturing, potentially expanding access in healthcare systems with limited oncology budgets. Global oncology access remains constrained by cost, and peptide alternatives could help close this gap.

Tumor-activated prodrug designs: Peptides can be engineered as prodrugs that become active only in the tumor microenvironment, activated by tumor-associated proteases like MMP-2. This approach could concentrate checkpoint blockade at the tumor while minimizing systemic immune activation, potentially reducing the immune-related adverse events (colitis, hepatitis, pneumonitis) that limit antibody checkpoint therapy.

Combination flexibility: Peptides can be readily conjugated to other therapeutic molecules, including radionuclides (as in PRRT), cytotoxic payloads, or other peptide sequences, creating multifunctional agents that antibodies cannot easily replicate.

Oral delivery potential: While no oral peptide checkpoint inhibitor exists today, macrocyclic peptides with non-natural backbones and D-amino acid incorporation are moving toward oral bioavailability. Cyclosporine, a cyclic peptide immunosuppressant, demonstrated decades ago that oral peptide drugs are achievable with the right structural modifications. An orally available checkpoint inhibitor would transform cancer treatment logistics, eliminating the infusion center visits that current antibody therapies require. For patients in rural areas or developing countries, this accessibility difference could determine whether they receive checkpoint therapy at all.

The Bottom Line

Peptide-based immune checkpoint inhibitors represent a structurally distinct approach to cancer immunotherapy that trades the high affinity and long duration of antibodies for better tumor penetration, lower manufacturing costs, and tunable pharmacokinetics. The macrocyclic peptide BMS-986189 has reached Phase 1 clinical trials with nanomolar PD-L1 inhibition. Peptide cancer vaccines combined with antibody checkpoint inhibitors have shown synergistic effects in both preclinical models and early clinical cases. The most likely near-term impact of peptides in checkpoint therapy is not replacing antibodies but complementing them: peptide vaccines generating tumor-specific immunity that checkpoint antibodies then sustain, and peptide-drug conjugates delivering checkpoint blockade specifically to the tumor microenvironment.

Frequently Asked Questions

What are peptide immune checkpoint inhibitors?

Peptide immune checkpoint inhibitors are small protein fragments (1-5 kilodaltons) designed to block the same immune checkpoint pathways as monoclonal antibodies like nivolumab and pembrolizumab. They target interactions such as PD-1/PD-L1 and CTLA-4 that tumors exploit to suppress anti-cancer immune responses. The macrocyclic peptide BMS-986189 achieved an IC50 of 1.03 nM against PD-L1 in Phase 1 testing. Peptides offer advantages in tumor penetration and manufacturing cost but have shorter half-lives than antibodies.

How do peptide checkpoint inhibitors compare to antibody checkpoint inhibitors?

Antibody checkpoint inhibitors (150 kDa) achieve picomolar binding affinity and circulate for weeks but penetrate poorly into dense solid tumors and cost $100,000-$250,000 annually. Peptide alternatives (1-5 kDa) achieve nanomolar affinity with hours-long half-lives but penetrate tumors more uniformly and are cheaper to manufacture. No peptide checkpoint inhibitor has FDA approval yet, while over a dozen antibody checkpoint inhibitors are approved across multiple cancer types.

What is AUNP12 peptide?

AUNP12 is a 29-amino acid branched peptide developed by Aurigene and Pierre Fabre as the first peptide specifically designed to block the PD-1/PD-L1 checkpoint interaction. It achieved subnanomolar potency with an EC50 of 0.72 nM in HEK293 cells expressing PD-L2 and 0.41 nM in rat PBMC proliferation assays. AUNP12 demonstrated dose-dependent restoration of T-cell proliferation and cytokine production suppressed by PD-L1 signaling in preclinical models.

Can peptide vaccines enhance checkpoint inhibitor therapy?

Peptide cancer vaccines generate tumor-specific T cells, while checkpoint inhibitors prevent those T cells from becoming exhausted. Dendritic cells pulsed with gp100 peptide-decorated liposomes enhanced anti-PD-L1 antibody efficacy in melanoma models (Yazdani et al., 2020). A neoantigen peptide vaccine combined with checkpoint inhibition induced tumor regression in a 2025 clinical case report (Amorelli et al., 2025). The combination outperforms either approach alone because it addresses both immune activation and immune suppression.

What are macrocyclic peptide checkpoint inhibitors?

Macrocyclic peptides are ring-shaped peptide structures that combine the target selectivity of peptides with improved stability and binding affinity approaching small molecules. BMS-986189, a macrocyclic PD-L1 inhibitor from Bristol-Myers Squibb, reached Phase 1 clinical trials with 1.03 nM potency. De novo designed macrocycles incorporating D-amino acids achieved further improvements in proteolytic stability (Guardiola et al., Chemical Science, 2021). Macrocycles represent the most clinically advanced class of peptide checkpoint inhibitors.

Are peptide checkpoint inhibitors FDA approved?

No peptide immune checkpoint inhibitor has received FDA approval as of early 2026. BMS-986189, a macrocyclic peptide PD-L1 inhibitor, reached Phase 1 clinical testing. AUNP12, a linear peptide PD-1/PD-L1 inhibitor, demonstrated subnanomolar potency in preclinical studies. Peptide cancer vaccines used in combination with approved antibody checkpoint inhibitors are in more advanced clinical development, with multiple Phase 1/2 trials completed or ongoing for various cancer types.